Ibandronic Acid a Review of its Use in the Treatment of Bone Metastases of Breast Cancer

Drugs

Volumn 66, Issue 5, 2006, Pages 711-728

  McCormack, Paul L ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CREATININE; DOXORUBICIN; ETIDRONIC ACID; GERANYLTRANSFERASE; IBANDRONIC ACID; INCADRONIC ACID; MATRIX METALLOPROTEINASE INHIBITOR; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TEGAFUR; URACIL; ZOLEDRONIC ACID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ADRENAL METASTASIS; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BONE METASTASIS; BONE NECROSIS; BONE PAIN; BREAST CANCER; CHILL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPEPSIA; ENZYMURIA; ESOPHAGITIS; FEVER; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATURIA; HUMAN; HYPOCALCEMIA; JAW; KIDNEY DYSFUNCTION; MAXIMUM ALLOWABLE CONCENTRATION; MYALGIA; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOLYSIS; PROTEINURIA; QUALITY OF LIFE; REVIEW; RISK FACTOR;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; HUMANS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS;

EID: 33646345591     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666050-00011     Document Type: Review

References (64)

1. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess 2004; 8 (4): 1-176
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27 (3): 165-76
3. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003 Nov 1; 21 (21): 4042-57
4. Hoskin PJ. Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case against. Clin Oncol 2004; 16 (2): 112-4
5. Coleman R. Guidelines for the use of bisphosphonates in bone metastases. EJC Suppl 2003 Sep; 1 (6): 299-306
6. Cameron D. Patient management issues in metastatic bone disease. Semin Oncol 2004 Oct; 31 (5 Suppl. 10): 79-82
7. Roche. European approval for Bondronat in major additional indication [online]. Available from URL: http://www.roche.com/med-cor-2003-11-04 [Accessed 2006 Jan 27]
8. Barrett J, Worth E, Bauss F, et al. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004 Sep; 44 (9): 951-65
9. El-Rayes BF, LoRusso PM. The role of bisphosphonates in the treatment of skeletal complications of breast cancer. Am J Cancer 2004; 3 (6): 369-75
10. Body JJ. Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia 2001 Oct; 6 (4): 477-85
11. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol 2005 May; 16 (5): 687-95
12. Fromigue O, Siwek B, Body JJ. Bisphosphonates modulate interactions between breast cancer cells and osteoblasts [abstract no. T333]. Bone 1998; 23 (5 Suppl.): 280
13. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9 (32): 2643-58
14. Mühlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991 Sep; 6 (9): 1003-11
15. Hiraga T, Williams PJ, Mundy GR, et al. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001 Jun 1; 61: 4418-24
16. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997 May 15; 99: 2509-17
17. Kurth AHA, Kim SZ, Sedlmeyer I, et al. Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J Bone Joint Surg Br 2000 Jan; 82-B (1): 126-30
18. Neudert M, Fischer C, Krempien B, et al. Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. Int J Cancer 2003 Nov 10; 107 (3): 468-77
19. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002 Nov 15; 62 (22): 6538-44
20. Yoneda T, Michigami T, Yi B, et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000 Jun 15; 88 (12 Suppl.): 2979-88
21. Dallas SL, Garrett IR, Oyajobi BO, et al. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease. Blood 1999 Mar 1; 93 (5): 1697-706
22. van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996 Aug 1; 98 (3): 698-705
23. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997 Sep 15; 57: 3890-4
24. Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000 Jun 1; 60: 2949-54
25. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000 Nov; 15 (11): 2211-21
26. Kurth AA, Kim SZ, Sedlmeyer I, et al. Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. Bone 2002 Jan; 30 (1): 300-6
27. Journe F, Chaboteaux C, Magne N, et al. Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines. Breast Cancer Res 2005 Dec 12; 8 (1): R2
28. Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003 Sep 30; 191 (2-3): 159-67
29. Pfister T, Bauss F, Body JJ. The risk of cumulative renal effects of intravenous (i.v.) bisphosphonates [abstract no. 859P]. Ann Oncol 2004; 15 Suppl. 3: iii226-7
30. Roche. Bondronat (ibandronic acid): product information [online]. Available from URL: http://www.emea.eu.int/humandocs/ Humans/EPAR/bondronat/bondronat.htm [Accessed 2006 Jan 24]
31. Leyland-Jones B. Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease. EJC Suppl 2004; 2 (5): 9-12
32. European Medicines Agency. Bondronat European Public Assessment Report: scientific discussion [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/bondronat/bondronat.htm [Accessed 2006 Jan 6]
33. Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004 Jun; 15 (6): 423-33
34. Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. MF 4265 Study Group. Ann Oncol 2003 Sep; 14 (9): 1399-405
35. Tripathy D, Lichinitzer M, Lazarev A, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. MF 4434 Study Group. Ann Oncol 2004 May; 15 (5): 743-50
36. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004 Mar 22; 90 (6): 1133-7
37. Lichinitser M, Coleman RE, Tjulandin SA. Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers [abstract no. 405]. EJC Suppl 2005; 3 (2): 113. Plus poster presented at the 13th European Cancer Conference (ECCO 13); 2005 Oct 30-Nov 3; Paris
38. Diel IJ, Body JJ, Lichinitser MR, et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004 Jul; 40 (11): 1704-12
39. Body JJ, Diel IJ, Bell R, et al. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 2004 Oct; 111 (3): 306-12
40. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. Support Care Cancer 2005 Dec; 13 (12): 975-86
41. De Cock E, Hutton J, Canney P, et al. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. Clin Ther 2005 Aug; 27 (8): 1295-310
42. Stephens JM, Aapro MS, Botteman MF, et al. A Markov model to evaluate the cost effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases [abstract no. 664]. J Clin Oncol 2005 Jun 1; 23 (Pt 1) Suppl. 16: 44s. Plus poster presented at the 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL)
43. Botteman M, Hay JW, Stephens JM, et al. A Markov model to evaluate the cost effectiveness of five bisphosphonate therapies in the prevention of bone complications in breast cancer patients with bone metastases: a German outpatient perspective [abstract no. 423]. EJC Suppl 2005; 3 (2): 119. Plus poster presented at the 13th European Cancer Conference (ECCO 13); 2005 Oct 30-Nov 3; Paris
44. Wardley A, Body JJ, Neary M. A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients [abstract no. 6123]. J Clin Oncol 2005 Jun 1; 23 (Pt I Suppl. 16): 558
45. th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL), 47
46. Diel IJ. Ibandronate: a well-tolerated intravenous and oral treatment for metastatic bone disease. EJC Suppl 2004; 2 (5): 13-6
47. Diel I, Pecherstorfer M, Body JJ, et al. Long-term safety of intravenous ibandronate for up to 4 years in metastatic breast cancer: an open-label trial [abstract no. 21-148]. Support Care Cancer 2005; 13 (6): 462-3
48. McLachlan SA, Cameron D, Murray R, et al. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Invest 2006; 26 (1): 43-8
49. Pecherstorfer M, Diel IJ, Bergstrom B. Long-term (4-year) safety of intravenous ibandronate in metastatic breast cancer: an open-label study [abstract no. 255]. EJC Suppl 2004 Mar; 2 (3): 130
50. Lyubimova NV, Kushlinsky NE, Lichinitser MR, et al. Renal safety of intravenous ibandronic acid in breast cancer patients with metastatic bone disease. Clin Drug Invest 2003; 23 (11): 707-16
51. Morris M. Bisphosphonates and jaw osteonecrosis: experience with ibandronate [abstract no. 1290]. EJC Suppl 2005 Oct; 3 (2): 372
52. Body JJ, Lichinitser M, Tjulandin SA, et al. Safety comparison of oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: phase III data [abstract no. 408]. EJC Suppl 2005; 3 (2): 114. Plus poster presented at the 13th European Cancer Conference (ECCO 13); 2005 Oct 30-Nov 3; Paris
53. Roche. Boniva (ibandronate sodium) tablets: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2003/21455_boniva_lbl.pdf [Accessed 2006 Jan 27]
54. Gainford MC, Dranitsaris G, Clemons M. Recent developments in bisphosphonates for patients with metastatic breast cancer. Br Med J 2005; 330 (7494): 769-73
55. Ross JR, Saunders Y, Edmonds PM, et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003 Aug 30; 327 (7413): 469-75
56. Neville-Webbe HL, Holen I, Coleman RE. The anti-tumour activity of bisphosphonates. Cancer Treat Rev 2002; 28 (6): 305-19
57. Rosen LS, Gordon DH, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004 Jan 1; 100 (1): 36-43
58. Body JJ, Diel I, Bell R. Profiling the safety and tolerability of bisphosphonates. Semin Oncol 2004 Oct; 31 (5 Suppl. 10): 73-8
59. Heidenreich A, Ohlmann C, Body JJ. Ibandronate in metastatic bone pain. Semin Oncol 2004 Oct; 31 (5 Suppl. 10): 67-72
60. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol 2004 Sep 1; 22 (17): 3587-92
61. Heidenreich A, Ohlmann C, Olbert P, et al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcemia due to metastatic urologic cancer [abstract no. 897]. EJC Suppl 2003 Sep; 1 (5): S270
62. Delea T, McKiernan J, Liss M, et al. Effects of skeletal complications on total medical care costs in women with bone metastases of breast cancer [abstract no. 68]. Bone 2004; 34 Suppl. 1: S86
63. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999 Jul; 7 (4): 271-9
64. Hillner BE, Weeks JC, Desch CE, et al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000 Jan; 18 (1): 72-9